You just read:

Ascentage Pharma to Release Updated Data of its Novel, Third-Generation BCR-ABL Inhibitor, HQP1351, in Chinese Chronic Myeloid Leukemia Patients in an Oral Presentation at the 61st American Society of Hematology Annual Meeting

News provided by

Ascentage Pharma

Nov 14, 2019, 05:00 ET